期刊
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
卷 12, 期 2, 页码 340-352出版社
SPRINGER
DOI: 10.1007/s11481-016-9721-6
关键词
Adeno-associated virus; Gene therapy; Lysosomal degrading enzyme; Proteomics; Radial arm water maze
资金
- NIH [DA028555, NS036126, NS034239, MH064570, NS043985, MH062261, AG043540]
- DOD [421-20-09A]
- Carol Swarts Emerging Neuroscience Fund
- Department of Pharmacology and Experimental Neuroscience
- Shoemaker Award for Neurodegenerative Research
Amyloid- (A) precursor protein (APP) metabolism engages neuronal endolysosomal pathways for A processing and secretion. In Alzheimer's disease (AD), dysregulation of APP leads to excess A and neuronal dysfunction; suggesting that neuronal APP/A trafficking can be targeted for therapeutic gain. Cathepsin B (CatB) is a lysosomal cysteine protease that can lower A levels. However, whether CatB-modulation of A improves learning and memory function deficits in AD is not known. To this end, progenitor neurons were infected with recombinant adenovirus expressing CatB and recovered cell lysates subjected to proteomic analyses. The results demonstrated Lamp1 deregulation and linkages between CatB and the neuronal phagosome network. Hippocampal injections of adeno-associated virus expressing CatB reduced A levels, increased Lamp1 and improved learning and memory. The findings were associated with the emergence of c-fos + cells. The results support the idea that CatB can speed A metabolism through lysosomal pathways and as such reduce AD-associated memory deficits.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据